Head-to-head · free
Ovid Therapeutics Inc. vs uniQure
OVID vs QURE — return on capital, cash generation, margins and balance sheet side by side.
OVID
3 / 5
measures where OVID leads
QURE
2 / 5
measures where QURE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | OVID · FY2025 | QURE · FY2025 |
|---|---|---|
| Revenue | $7.3M | — |
| Net income | (17.4M) | (199.0M) |
| Revenue growth (yearly, multi-year) | -68.1% | -47.8% |
| Free cash flow | (38.3M) | (178.4M) |
| Free cash flow margin | -528.6% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -17.5% | — |
| Gross margin | — | 89.5% |
| Operating margin | -585.2% | -1166.8% |
| Net debt / EBITDA | 0.31x | 0.18x |
Figures are as reported by each company; latest fiscal year shown.
Where Ovid Therapeutics Inc.'s cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where uniQure's cash went (FY2025)
- Capital spending
- $439000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free